Skip to main content
eScholarship
Open Access Publications from the University of California

Scholarly Works (6 results)

  • Thesis
  • Peer Reviewed
UC Irvine Electronic Theses and Dissertations (2017)

Mesenchymal Stem Cell-derived Exosomes Promote Neurologic Recovery in Experimental Autoimmune Encephalomyelitis model of Multiple Sclerosis

By

Milad Riazifar

Doctor of Philosophy in Pharmacological Sciences

University of California, 2017

Professor Weian Zhao, Chair

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) in which autoreactive T cells attack CNS, resulting in demyelination, neuronal injury and death, which account for the neurological disability. Preclinical studies revealed immunomodulatory and immunosuppressive properties of mesenchymal stem cell (MSC) to treat MS. However, Lung entrapment, maldifferentiation, phenotype change and potentially tumor formation are current challenges for stem cell therapy. The much smaller size of MSC-derived exosomes (Exo), allow reduced lung entrapment, achieve superior biocompatibility, are more stable and expose fewer risks, which together makes them an attractive alternative.

Here, using experimental autoimmune encephalomyelitis (EAE) as a MS mouse model (n=30), we show that systemic injection of MSC-Exo (150 μg) result in sustained recovery and improved motor function (p<0.01). This recovery is associated reduced in neuroinflammation and increased remyelination (p<0.05). Biodistribution experiments show that Exo were mostly found in liver and spleen in healthy and EAE mice, but also in spinal cords of EAE, but not healthy animals. This suggests the involvement Exo in the spinal cord lesion repair. Using Foxp3-eGFP Treg reporter C57BL/6 mice (n=20) we showed that number of CD4+/CD25+/Foxp3+ regulatory T cells (Tregs) increase within the spinal cords of Exo treated animals compared to control (43.3% vs. 26.3%; p<0.05). Systemic injection of MSC-Exo results in clinical recovery in these mice as well (p<0.05). Additionally, co-culture of MSC-Exo (20 μg) with activated T cells result in reduced T cell proliferation and increased Treg numbers in vitro compared to control (14.9 ± 3.5 vs. 5.2 ± 1.2; p<0.05), proposing the capability of Exo to induce Tregs. Eliminating RNA by UV light reduced the function of the exosomes in Treg induction (p<0.05), and deep RNA sequencing revealed that the MSC-Exo are highly enriched in mRNAs with anti-inflammatory properties (i.e. indoleamine 2, 3-dioxygenase, Thymosin β). Similarly, proteomics identified numerous proteins with anti-inflammatory and neuroprotective properties in the Exo fractions (i.e. Glypican-1, Galectin-1, HSP70). In summary, this study describes the potential of MSC-Exo as therapeutics in autoimmune neurodegenerative diseases

    Cover page: Therapeutic Applications of Mesenchymal Stem Cell Vesicles
    • Article
    • Peer Reviewed
    UC Irvine Previously Published Works (2017)
    Stem cells are critical to maintaining steady-state organ homeostasis and regenerating injured tissues. Recent intriguing reports implicate extracellular vesicles (EVs) as carriers for the distribution of morphogens and growth and differentiation factors from tissue parenchymal cells to stem cells, and conversely, stem cell-derived EVs carrying certain proteins and nucleic acids can support healing of injured tissues. We describe approaches to make use of engineered EVs as technology platforms in therapeutics and diagnostics in the context of stem cells. For some regenerative therapies, natural and engineered EVs from stem cells may be superior to single-molecule drugs, biologics, whole cells, and synthetic liposome or nanoparticle formulations because of the ease of bioengineering with multiple factors while retaining superior biocompatibility and biostability and posing fewer risks for abnormal differentiation or neoplastic transformation. Finally, we provide an overview of current challenges and future directions of EVs as potential therapeutic alternatives to cells for clinical applications.
      Cover page: Stem Cell Extracellular Vesicles: Extended Messages of RegenerationCreative Commons 'BY' version 4.0 license
      • Article
      • Peer Reviewed
      UC Irvine Previously Published Works (2020)
      Mesenchymal stem or stromal cells are currently under clinical investigation for multiple diseases. While their mechanism of action is still not fully elucidated, vesicles secreted by MSCs are believed to recapitulate their therapeutic potentials to some extent. Microvesicles (MVs), also called as microparticles or ectosome, are among secreted vesicles that could transfer cytoplasmic cargo, including RNA and proteins, from emitting (source) cells to recipient cells. Given the importance of MVs, we here attempted to establish a method to isolate and characterize MVs secreted from unmodified human bone marrow derived MSCs (referred to as native MSCs, and their microvesicles as Native-MVs) and IFNγ stimulated MSCs (referred to as IFNγ-MSCs, and their microvesicles as IFNγ-MVs). We first describe an ultracentrifugation technique to isolate MVs from the conditioned cell culture media of MSCs. Next, we describe characterization and quality control steps to analyze the protein and RNA content of MVs. Finally, we examined the potential of MVs to exert immunomodulatory effects through induction of regulatory T cells (Tregs). Secretory vesicles from MSCs are promising alternatives for cell therapy with applications in drug delivery, regenerative medicine, and immunotherapy.
        Cover page: Isolation and characterization of microvesicles from mesenchymal stem cells
        • Article
        • Peer Reviewed
        UC Irvine Previously Published Works (2016)
        Systemic administration of mesenchymal stem cells (MSCs) affords the potential to ameliorate the symptoms of Multiple Sclerosis (MS) in both preclinical and clinical studies. However, the efficacy of MSC-based therapy for MS likely depends on the number of cells that home to inflamed tissues and on the controlled production of paracrine and immunomodulatory factors. Previously, we reported that engineered MSCs expressing P-selectin glycoprotein ligand-1 (PSGL-1) and Sialyl-Lewis(x) (SLeX) via mRNA transfection facilitated the targeted delivery of anti-inflammatory cytokine interleukin-10 (IL-10) to inflamed ear. Here, we evaluated whether targeted delivery of MSCs with triple PSGL1/SLeX/IL-10 engineering improves therapeutic outcomes in mouse experimental autoimmune encephalomyelitis (EAE), a murine model for human MS. We found PSGL-1/SLeX mRNA transfection significantly enhanced MSC homing to the inflamed spinal cord. This is consistent with results from in vitro flow chamber assays in which PSGL-1/SleX mRNA transfection significantly increased the percentage of rolling and adherent cells on activated brain microvascular endothelial cells, which mimic the inflamed endothelium of blood brain/spinal cord barrier in EAE. In addition, IL-10-transfected MSCs show significant inhibitory activity on the proliferation of CD4(+) T lymphocytes from EAE mice. In vivo treatment with MSCs engineered with PSGL-1/SLeX/IL-10 in EAE mice exhibited a superior therapeutic function over native (unmodified) MSCs, evidenced by significantly improved myelination and decreased lymphocytes infiltration into the white matter of the spinal cord. Our strategy of targeted delivery of performance-enhanced MSCs could potentially be utilized to increase the effectiveness of MSC-based therapy for MS and other central nervous system (CNS) disorders.
          Cover page: Mesenchymal stem cells engineered to express selectin ligands and IL-10 exert enhanced therapeutic efficacy in murine experimental autoimmune encephalomyelitisCreative Commons 'BY' version 4.0 license
          • Article
          • Peer Reviewed
          UC Irvine Previously Published Works (2016)
          The delivery of therapeutics to the central nervous system (CNS) remains a major challenge in part due to the presence of the blood-brain barrier (BBB). Recently, cell-derived vesicles, particularly exosomes, have emerged as an attractive vehicle for targeting drugs to the brain, but whether or how they cross the BBB remains unclear. Here, we investigated the interactions between exosomes and brain microvascular endothelial cells (BMECs) in vitro under conditions that mimic the healthy and inflamed BBB in vivo. Transwell assays revealed that luciferase-carrying exosomes can cross a BMEC monolayer under stroke-like, inflamed conditions (TNF-α activated) but not under normal conditions. Confocal microscopy showed that exosomes are internalized by BMECs through endocytosis, co-localize with endosomes, in effect primarily utilizing the transcellular route of crossing. Together, these results indicate that cell-derived exosomes can cross the BBB model under stroke-like conditions in vitro. This study encourages further development of engineered exosomes as drug delivery vehicles or tracking tools for treating or monitoring neurological diseases.
            Cover page: Elucidation of Exosome Migration across the Blood-Brain Barrier Model In Vitro.Creative Commons 'BY' version 4.0 license
            • Article
            • Peer Reviewed
            UC Irvine Previously Published Works (2019)
            To dissect therapeutic mechanisms of transplanted stem cells and develop exosome-based nanotherapeutics in treating autoimmune and neurodegenerative diseases, we assessed the effect of exosomes secreted from human mesenchymal stem cells (MSCs) in treating multiple sclerosis using an experimental autoimmune encephalomyelitis (EAE) mouse model. We found that intravenous administration of exosomes produced by MSCs stimulated by IFNγ (IFNγ-Exo) (i) reduced the mean clinical score of EAE mice compared to PBS control, (ii) reduced demyelination, (iii) decreased neuroinflammation, and (iv) upregulated the number of CD4+CD25+FOXP3+ regulatory T cells (Tregs) within the spinal cords of EAE mice. Co-culture of IFNγ-Exo with activated peripheral blood mononuclear cells (PBMCs) cells in vitro reduced PBMC proliferation and levels of pro-inflammatory Th1 and Th17 cytokines including IL-6, IL-12p70, IL-17AF, and IL-22 yet increased levels of immunosuppressive cytokine indoleamine 2,3-dioxygenase. IFNγ-Exo could also induce Tregs in vitro in a murine splenocyte culture, likely mediated by a third-party accessory cell type. Further, IFNγ-Exo characterization by deep RNA sequencing suggested that IFNγ-Exo contains anti-inflammatory RNAs, where their inactivation partially hindered the exosomes potential to induce Tregs. Furthermore, we found that IFNγ-Exo harbors multiple anti-inflammatory and neuroprotective proteins. These results not only shed light on stem cell therapeutic mechanisms but also provide evidence that MSC-derived exosomes can potentially serve as cell-free therapies in creating a tolerogenic immune response to treat autoimmune and central nervous system disorders.
              Cover page: Stem Cell-Derived Exosomes as Nanotherapeutics for Autoimmune and Neurodegenerative Disorders.
              Top